Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Lynozyfic™ (linvoseltamab), advanced a broad early-stage program in newly diagnosed patients, and entered a global collaboration with Tessera Therapeutics to develop TSRA-196, an in vivo “Gene Writing” candidate for alpha-1 antitrypsin deficiency. These updates highlight Regeneron's push to extend its oncology footprint and expand into genetic medicines, potentially broadening its future sources of revenue beyond current flagship products. Next, we'll explore how Lynozyfic's early multiple myeloma data could reshape Regeneron's investment narrative and long-term growth profile. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Regeneron, you have to believe its core eye and immunology franchises can hold up while a broad pipeline, including oncology and genetic medicines, matures into meaningful revenue. The latest Lynozyfic data and Tessera “Gene Writing” deal s
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- 2 Reasons to Buy Regeneron Stock Like There's No Tomorrow [Yahoo! Finance]Yahoo! Finance
- Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Morgan Stanley from $767.00 to $768.00. They now have an "equal weight" rating on the stock.MarketBeat
- Biohaven jumps on early-stage data for antibody drug conjugate combo [Seeking Alpha]Seeking Alpha
- 3 Low-Volatility Stocks We're Skeptical Of [Yahoo! Finance]Yahoo! Finance
- Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Wells Fargo & Company from $700.00 to $745.00. They now have an "equal weight" rating on the stock.MarketBeat
REGN
Earnings
- 10/28/25 - Beat
REGN
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- REGN's page on the SEC website